M yelofibrosis is manifested as primary myelofibrosis, post-essential throm bocythemia myelofibrosis, or postpolycythemia vera myelofibrosis and is characterized by clinical signs (e.g., progressive anemia, bone marrow fibrosis, and splenomegaly) and a constellation of debilitating symptoms (fatigue, weakness, bone pain, a hypercatabolic state, and weight loss). 1 Survival in myelofibrosis is related to the number of risk factors and ranges from 2 to 4 years among patients with two or more risk factors (intermediate-2 or high risk) to 8 to 11 years among patients with no risk factors or one risk factor (intermediate-1 or low risk) (see Table 1A in the Supplementary Appendix, available with the full text of this article at NEJM.org). 2-4 Conventional drugs used to treat myelofibrosis provide only palliative benefits and are not approved for this indication. 5 The discovery of JAK2 V617F, a somatic gain-offunction mutation in the Janus kinase 2 (JAK2) in classic Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera, and primary myelofibrosis, generated interest in the development of JAK2-targeted therapies for these diseases. 6, 7 The JAK2 V617F mutation is present in approximately 50% of patients with myelofibrosis. Some clinical signs of the disease, such as anemia and splenomegaly, and the risk of transformation to acute myeloid leukemia (AML) have been related to JAK2 V617F mutational status or the JAK2 V617F allele burden. [8] [9] [10] Other mutations in the JAK2 and MPL (thrombopoietin receptor) genes that also result in an exaggerated JAK2 signaling 11 collectively point to unchecked activation of JAK2 as a potential mechanistic cause of Ph-negative myeloproliferative neoplasms. INCB018424, a potent, selective inhibitor of JAK1 and JAK2, has been shown to be effective in preclinical studies in models of myeloproliferative neoplasms. 12 We describe the clinical evaluation of a JAK1 and JAK2 inhibitor in myelofibrosis.
Me thods

Eligibility Criteria
Patients 18 years of age or older with primary myelofibrosis, post−essential thrombocythemia myelofibrosis, or post−polycythemia vera myelofibrosis (according to World Health Organization criteria revised in 2001) 13 were eligible for enrollment if they required therapy, had had a relapse, or had severe side effects from therapy or disease that was refractory to previous therapy. Patients with newly diagnosed disease were eligible if they had intermediate-or high-risk disease according to the Lille scoring system. 14 (The Lille system defines risk according to the number of adverse prognostic factors [a hemoglobin level of <10 g per deciliter, or a white-cell count of <4×10 9 or >30×10 9 per liter]: 0 [low risk], 1 [intermediate risk] , and 2 [high risk].) Patients with newly diagnosed disease also were eligible if they had symptomatic splenomegaly (or hepatomegaly in patients who had undergone splenectomy) that was palpable 10 cm or more below the left costal margin.
Additional eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. 15 (The ECOG performance status is graded on a scale of 0 to 5, with a higher score indicating a greater severity of illness. A score of 0 indicates that the patient is fully active and able to carry out all activities without restriction, a score of 1 indicates that the patient is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature [e.g., light housework or office work], and a score of 2 indicates that the patient is ambulatory and capable of all self-care but is unable to carry out any work activities and is out of bed more than 50% of waking hours.)
Other eligibility criteria included an absolute neutrophil count of more than 1.5×10 9 per liter, a platelet count of more than 100×10 9 per liter, a bilirubin level of 2.0 mg per deciliter (34 µmol per liter) or less, an alanine aminotransferase level of 2.5 times the upper limit of the normal range or less, and a creatinine level of 2.5 mg per deciliter (220 µmol per liter) or less. Patients could not have received therapy for myelofibrosis for 2 weeks before enrollment, and they could not have received busulfan or pegylated interferon for 4 weeks before enrollment. A negative serum pregnancy test was required in women of child-bearing potential, and effective contraception in all men and women of child-bearing potential was mandatory. Patients were excluded if they were pregnant or nursing, if they had another malignant condition (except nonmelanoma skin cancer or cervical intraepithelial neoplasia) or known active hepatitis infection, if they were positive for the human immunodeficiency virus, or if they were receiving glucocorticoid therapy (equivalent to prednisone at a dose of >10 mg per day) or if therapy with cytochrome P450 (CYP3A4 and CYP1A2) inhibitors or inducers was being administered or was planned.
Study Design
This phase 1−2 study was approved by the institutional review boards of the M.D. Anderson Cancer Center and Mayo Clinic and was conducted in accordance with the principles of the Declaration of Helsinki. All patients provided written informed consent. The sponsor of the study, Incyte, supplied INCB018424 tablets that were administered orally in an outpatient setting. Both once-daily and twice-daily dose schedules were evaluated in the phase 1 part of the study with the use of a standard 3+3 cohort design (3 to 6 patients per dose cohort) to determine safety and tolerability and to establish dose-limiting toxicity and the maximum tolerated dose. On the basis of an expanded cohort of 27 patients in the group of patients who received the maximum tolerated dose, it was predicted that there would be a greater than 90% chance of one or more adverse events, with a 10% underlying prevalence rate. Similarly, if the response rate was 10% or greater, the probability of one response or more would be more than 90%. Several alternative twice-daily dose schedules (below the maximum tolerated dose) were studied in the phase 2 part of the study. Four weeks of daily oral therapy was considered to constitute one cycle.
Patients were followed for a median of 14.7 months. The response was evaluated with the use of the response criteria of the International Working Group for Myelofibrosis Research and Treatment (Table 1B in the Supplementary Appendix). The treatment plan, response assessment, and laboratory correlates are described in the Supplementary Appendix.
The first author and the sponsor of the study wrote the first draft of the manuscript, and all of the authors made the decision to submit the article for publication. All authors vouch for the accuracy and completeness of the reported data. The authors also certify that the study as reported conforms with the protocol (for details, see the protocol, available at NEJM.org).
R esult s
Patients and Dose Schedules
A total of 153 patients with advanced primary myelofibrosis, post−essential thrombocythemia myelofibrosis, or post−polycythemia vera myelofibrosis were enrolled (Table 1, and Table 2 in the Supplementary Appendix). The starting dose of INCB018424 was 25 mg twice daily followed by escalation to 50 mg twice daily. Subsequently, once-daily doses were also evaluated, from 25 mg up to 200 mg once daily. Thrombocytopenia was identified as the dose-limiting toxic effect, and 25 mg twice daily and 100 mg once daily were identified as the maximum tolerated doses. However, 2 of 6 patients who received 100 mg once daily had clinically significant thrombocytopenia during the second month of therapy; therefore, additional patients were added to the cohorts of patients who received 25 mg twice daily and 50 mg once daily.
In the phase 2 part of the study, additional dosing schedules were studied in succession, with defined enrollment targets and additional evaluations ( Fig. 1 in the Supplementary Appendix) to identify an effective dosing schedule with a reduced incidence of thrombocytopenia. These schedules were as follows: 25 mg twice daily, with a reduction to 10 mg twice daily after two cycles (2 months) of therapy (induction-maintenance); 10 mg twice daily, with allowance for dose escalation after three cycles (3 months) if there was no response and no toxicity; and 10 mg twice daily (in patients with baseline platelet counts of 100×10 9 to 200×10 9 per liter) or 15 mg twice daily (in patients with baseline platelet counts of >200×10 9 per liter), with allowance for dose increases (monthly, 5-mg twice-daily increments) up to 25 mg twice daily, if there was no response and no toxicity (individualized dose adjustment). The baseline characteristics of the patients in these groups were well balanced ( received 50 mg once daily (41%), and lowest among the 27 patients who received 10 mg twice daily (30%) (Fig. 1A) . None of the patients who received 25 mg once daily had clinical improvement. Clinical improvement was observed in 3 of 4 patients receiving 50 mg twice daily, 3 of 6 patients receiving 100 mg once daily, and 2 of 3 patients receiving 200 mg once daily, but these patients required dose reductions because of thrombocytopenia. Among patients who had a response according to the International Working Group criteria, the response was maintained after 12 months of therapy, in 71% of patients who received 10 mg twice daily, 73% of patients who received 15 mg twice daily, 78% of patients who received 25 mg twice daily, and 75% of patients who received 50 mg once daily. The majority of patients (70% of patients who received 10 mg twice daily, 82% of patients who received 15 mg twice daily, and 77% of patients who received 25 mg twice daily) had a 25% or greater reduction in spleen size while receiving therapy (Fig. 1B) . This reduction occurred within the first 1 to 2 months of therapy, was durable beyond 1 year of therapy in all 16 patients for whom data were available at 1.5 years and all 8 patients for whom data were available at 2 years ( Fig. 1C) , and was similar among patients who received 15 mg twice daily (with individualized dose adjustment for an inadequate response and no toxicity) and those who received 25 mg twice daily (based on the intention-to-treat analysis) (Fig. 1D) . Although the best response was noted in the subgroup of patients who started with and continued to receive 25 mg twice daily, 60% of the patients who started with 25 mg twice daily required dose reductions because of thrombocytopenia; this suggests an advantage of initiating therapy at a dose of 15 mg twice daily.
A post hoc subgroup analysis showed that the proportion of patients with a response in the pooled groups of patients who received 15 mg twice daily and 25 mg twice daily (the most effective regimens) was similar among the 61 patients with the JAK2 V617F mutation and the 11 patients without the mutation (response rate, 51%; exact 95% confidence interval [CI], 31 to 61; and 45%; 95% CI, 23 to 83) as well as among 37 patients with primary myelofibrosis (response rate, 49%; 95% CI, 34 to 68), 22 patients with post−polycythemia vera myelofibrosis (response rate, 45; 95% CI, 32 to 76), and 13 patients with post−essential thrombocythemia myelofibrosis (response rate, 62%; 95% CI, 14 to 68).
Twenty-four patients who received 15 mg twice daily underwent magnetic resonance imaging (MRI) measurement of spleen and liver volume as an objective measure of response (at baseline and after one, three, and six cycles of treatment). A reduction in spleen volume detected by MRI paralleled a reduction in spleen size detected by physical examination: after 6 months of therapy, the median reduction in spleen volume was 33% and the median reduction in spleen length was 52% (Fig. 2 in the Supplementary Appendix). In 6 patients with hepatomegaly (an increase in liver volume that was more than two times the normal volume), the liver volume decreased by 14% after six cycles (6 months) of treatment.
A total of 28 patients who received 25 mg twice daily or 15 mg twice daily (the most active regimens for splenomegaly reduction) were transfusion-dependent at enrollment. After a median treatment duration of 12 weeks, 4 patients (14%) had transfusion independence (clinical improvement according to the International Working Group) for a median duration of 20 months. Patients with low platelet or neutrophil counts were not eligible for participation in the study; hence, no response evaluation according to the International Working Group was possible for these variables. The mean baseline white-cell count decreased after 3 months of therapy (P = 0.001) in patients who received 15 mg twice daily or 25 mg twice daily, from 29.8×10 9 to 16.0×10 9 per liter, and these counts remained stable through 1 year. Sixteen of 17 patients with elevated platelet counts at baseline (mean, 728×10 9 per liter) had reduced platelet counts at 3 months (mean, 336×10 9 per liter): of the 10 with normalized platelet counts at 3 months, 7 had counts that remained normal throughout year 1. Baseline CD34+ cell counts also decreased slightly after 3 months of therapy (from a mean of 583 to 398 cells per cubic millimeter) in 25 patients for whom serial measurements were available.
Symptomatic and Functional Improvements
After 1 month of therapy, the majority of patients who received INCB018424 at a dose of 10 mg twice daily to 25 mg twice daily had more than 50% improvement in total or individual symptom scores according to the Myelofibrosis Symptom Assessment Form (MFSAF) (on a scale of 0 to 10, with 0 indicating no symptoms and 10 indicating maximal symptoms) ( Table 3 in the Supplementary Appendix). This symptom response was durable through 6 months of therapy ( Fig. 2A) . Although the dose of 10 mg twice daily was suboptimal for the reduction of splenomegaly, the improvement in symptoms with this dose was similar to the improvement associated with 15 mg twice daily and 25 mg twice daily (Fig.  2B) . A reduction in abdominal discomfort and pain accompanied the reduction in spleen size. The mean score for pruritus (in 45% of patients who completed the MFSAF) was decreased after 2 weeks of therapy as compared with baseline (0.8 vs. 3.5, P<0.001), and the improvement was maintained through 12 cycles (12 months) of therapy. Patients with myelofibrosis walk 60 to 90 m less than agematched healthy controls in a 6-minute walk test. 18 Twenty-seven patients in this study underwent the 6-minute walk test; an improvement in their ability to walk in this test by 34 m after 1 month, 57 m after 3 months, and 71 m after 6 months of therapy was observed. Study patients started to gain weight after as few as two cycles (2 months) of therapy (Fig. 2C) ; this weight gain was more pronounced in patients in the lowest quartile for bodymass index at baseline than in those in the highest quartile. The median weight gain after 1 year of therapy was 6.6 kg in patients who received 10 mg twice daily, 9.4 kg in patients who received 15 mg twice daily, and 7.1 kg in patients who received 25 mg twice daily. Overall, the performance status of patients who received therapy improved over time (see the Supplementary Appendix).
Effect on JAK2 V617F Allele Burden and Biologic Markers of Myelofibrosis
At baseline, more than half the patients had a JAK2 V617F allele burden that was greater than 75% (Table 1 ). In 34 patients for whom data were available, the mean maximal suppression of 13% from baseline was seen after 12 cycles of therapy (4 patients had a 30 to 40% reduction and 1 had a decrease from 38 to 5%). Plasma levels of various biomarkers, including several proinflammatory cytokines, were significantly higher at baseline in 23 patients who received 25 mg twice daily than in healthy controls (Fig. 3A) . Levels of leptin, a hormone derived from adipose tissue, and erythropoietin were lower than normal. After one cycle of therapy, all biomarker levels decreased, except for levels of leptin and erythropoietin, which increased. These changes were not related to the patients' JAK2 mutational status or disease subtype (Fig. 3B) . Reductions in plasma levels of selected cytokines correlated with symptomatic improvements (Fig. 3C) .
In addition, constitutively phosphorylated signal transducer and activator of transcription 3 (STAT3), phosphorylated signal transducer and activator of transcription 5 (STAT5), or both were observed in patients with myelofibrosis at baseline, regardless of their JAK2 V617F mutational status (data shown in Fig. 3A in the Supplementary Appendix). A dose-and time-dependent reduction of phosphorylated STAT3 was observed after INCB018424 treatment ( Fig. 3B and 3C in the Supplementary Appendix).
Safety and Adverse Events
Among the 153 patients enrolled in this study, the median duration of therapy was more than 1 year (>14.7 months), and 115 patients (75%) were still receiving therapy as of this writing. Nonhematologic toxic effects related to therapy were infrequent (in <10% of patients) and of low grade (Table 2) . Hematologic toxic effects included anemia and grade 3 or 4 thrombocytopenia (Table 3) . Thrombocytopenia was unrelated to JAK2 V617F mutational status, occurred more often in patients with a baseline platelet count of less than 200×10 9 per liter (data not shown), and was reversible within 1 to 3 weeks after dose interruption; most patients resumed treatment at a lower dose. The incidence of thrombocytopenia was significantly lower among the 35 patients who received the 15-mg dose twice daily than among the 47 patients who received the 25-mg dose twice daily (3% vs. 29%), even though patients who received 15 mg twice daily underwent subsequent dose increases to 20 mg twice daily (approximately 25% of patients) or 25 mg twice daily (approximately 10% of patients). In contrast, the dose was decreased or interrupted in 60% of patients who received 25 mg twice daily because of hematologic toxicity in the first year of therapy.
Mean hemoglobin levels decreased during the first three to four cycles of therapy and then stabilized or improved with continued treatment (Fig. 4 in the Supplementary Appendix). There was a lower incidence of new-onset anemia among Panel A shows the proportion of patients who received INCB018424 at a dose of 10 to 25 mg twice daily who had at least a 50% decrease in the individual symptom score on the Modified Myelofibrosis Symptom Assessment Form (MFSAF) 17 relative to baseline that was durable for 6 months. After 1 month, 75%, 82%, 52%, and 63% of the patients had at least a 50% improvement in scores for night sweats, itching, abdominal pain or discomfort, and bone or muscle pain, respectively. After 6 months, 88%, 82%, 55%, and 40% of the patients had at least a 50% improvement in scores for night sweats, itching, abdominal pain or discomfort, and bone or muscle pain, respectively. A combined symptom score comprising scores for night sweats, itching, abdominal pain or discomfort, and bone or muscle pain was calculated, and the proportion of patients with a 50% or greater improvement relative to baseline was determined. As shown in Panel B, similar proportions of patients had improvement in symptoms at doses of 10 mg twice daily (75% at 1 month and 63% at 6 months), 15 mg twice daily (56% at 1 month and 56% at 6 months), or 25 mg twice daily (55% at 1 month and 64% at 6 months). As shown in Panel C, an increase in weight was observed after INCB018424 treatment in patients who received twice-daily doses of 10 mg to 25 mg; this increase was more pronounced in patients in the lowest quartile of the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) (16.2 to 22.5) than in those in the highest quartile (27.9 to 49.7). I bars denote standard errors. patients who received 15 mg twice daily than among the patients who received 25 mg twice daily (8% vs. 27%) ( Table 3 ) and a lower proportion of patients who required transfusions (4.7% vs. 20%) during therapy. Serious adverse events occurred in 59 patients, of whom 12 had serious adverse events that were considered to be at least possibly related to treatment ( Table 4 in the Supplementary Appendix). In 3 patients, there was transformation to AML. During 2 or more years of follow-up, 38 patients discontinued treatment because of withdrawal of 
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consent, the investigator's decision to discontinue treatment, or other reasons (in 24 patients), progressive disease (in 4 patients), toxic effects (in 2 patients), intercurrent illness (in 3 patients), and death (in 5 patients) ( Table 5 in the Supplementary Appendix). Seventeen of 153 patients died during the follow-up period (overall survival, 84%) (Fig. 5A in the Supplementary Appendix), of whom 5 died during therapy and 3 died within 30 days after discontinuation of therapy (90% survival when only deaths that occurred during the study were considered) (Fig. 5B in the Supplementary Appendix).
The pharmacokinetic and pharmacodynamic properties of therapy are described in the Supplementary Appendix.
Discussion
In this phase 1−2 study, we found that INCB018424, an oral JAK1 and JAK2 inhibitor, was associated with clinical benefits in patients with advanced (intermediate-2 or high-risk) myelofibrosis. A starting dose of 15 mg twice daily with individualized dose adjustment was found to be the most effective and safest dose of INCB018424. This agent was associated with rapid and sustained reduction of splenomegaly, resolution of constitutional symptoms, improvement of performance status and exercise capacity, and weight gain. These durable improvements (median follow-up, >1 year) were independent of JAK2 mutational status or the cause of disease. Although a small fraction of patients with transfusion-dependent anemia became transfusion-independent, new-onset anemia developed in a similar percentage of patients, indicating that improvement in anemia is not a major benefit of therapy. Thrombocytopenia, an expected toxic effect, was defined as the doselimiting toxic effect.
Splenomegaly and associated symptoms such as abdominal pain compromise the quality of life in patients with myelofibrosis, 17, 19 and alleviation of these aspects of myelofibrosis by INCB018424 is an important clinical benefit. The reduction in splenomegaly observed in most patients was not predicted, and it occurred without deterioration in hematologic variables or tumor-cell lysis. The spleen is thought to be a site of hematopoiesis in myelofibrosis; however, a reduction in spleen size did not compromise hematopoiesis. Although further investigation is needed to clarify the specific basis for the reduction in splenomegaly by therapy targeted at JAK1 and JAK2, our working hypothesis is that JAK2 inhibition is responsible for abrogation of neoplastic cell proliferation in the spleen.
Symptoms of myelofibrosis not directly related to splenomegaly, including night sweats, fevers, fatigue, weight loss, and pruritus, also improved in response to INCB018424. It has previously been reported (and confirmed here) (Fig. 3A) that patients with myelofibrosis have high levels of circulating inflammatory cytokines, such as interleukin-6, 20 that probably contribute to the hypercatabolic state and constitutional symptoms such as weight loss and fatigue. 21, 22 Recognizing that many proinflammatory cytokines signal through a JAK1-dependent cellular pathway, we recently found that JAK1 is constitutively active in peripheral-blood cells in patients with myelofibrosis. 12 A reduction in signal transduction and cytokine levels, including interleukin-6, tumor necrosis factor α, and macrophage inflammatory protein 1β, presumably through JAK1 and JAK2 inhibition, paralleled improvements in the patients' systemic symptoms (i.e., a decrease in the composite symptom score) after therapy (Fig. 3C) .
Results demonstrating the presence of constitutively phosphorylated STAT3 that was independent of JAK2 V617F mutational status (Fig. 3A in the Supplementary Appendix) provide evidence of activated JAK signaling in myelofibrosis with both wild-type and mutated JAK2 and raise the possibility of alternative pathways of JAK activation in JAK2 V617F−negative myelofibrosis. Suppression of phosphorylated STAT3 (Fig. 3B and 3C in the Supplementary Appendix) and the down-modulation of inflammatory cytokine levels and their signaling in patients with either JAK2 V617F or wild-type JAK2 after INCB018424 treatment provide a rational biologic explanation for the finding that the response to therapy was independent of JAK2 V617F mutational status.
The majority of patients in this study (65%) were in the high-risk category, according to the International Prognostic Scoring System, 2 with an expected median survival of 27 months. Although the overall survival rate of 84% (90% survival when only deaths that occurred during the study were considered) in this study with up to 2 years of follow-up is encouraging, longer follow-up and a study with a concurrent control group are needed to definitively establish any survival benefit of this therapy. On the basis of limited historical data, the expected frequency of AML transformation among patients with myelofibrosis is 0.06 per patientyear. 8, 23 In the present study involving 153 patients with a median follow-up of approximately 15 months (>190 patient-years), 3 cases of transformation to AML were observed, as compared with an expected incidence of 11 cases.
In conclusion, this study shows clinical responses to a JAK1 and JAK2 inhibitor, INCB018424, in patients with advanced myelofibrosis. The clinical benefits observed with this targeted therapy suggest the potential to address important unmet medical needs in patients with myelofibrosis. On the basis of the results of this study, two controlled, phase 3 randomized trials have been initiated.
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